637 related articles for article (PubMed ID: 22716160)
1. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Zuardi AW; Crippa JA; Hallak JE; Bhattacharyya S; Atakan Z; Martin-Santos R; McGuire PK; Guimarães FS
Curr Pharm Des; 2012; 18(32):5131-40. PubMed ID: 22716160
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
4. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
5. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
[TBL] [Abstract][Full Text] [Related]
6. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.
Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA
Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462
[No Abstract] [Full Text] [Related]
8. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; Seal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK
Neuropsychopharmacology; 2010 Feb; 35(3):764-74. PubMed ID: 19924114
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol as a potential treatment for psychosis.
Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies.
Roser P; Haussleiter IS
Curr Pharm Des; 2012; 18(32):5141-55. PubMed ID: 22716153
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW
CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340
[TBL] [Abstract][Full Text] [Related]
12. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
13. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
14. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids, reward processing, and psychosis.
Gunasekera B; Diederen K; Bhattacharyya S
Psychopharmacology (Berl); 2022 May; 239(5):1157-1177. PubMed ID: 33644820
[TBL] [Abstract][Full Text] [Related]
16. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
17. Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.
Ghelani A
Early Interv Psychiatry; 2024 Jan; 18(1):10-17. PubMed ID: 37038248
[TBL] [Abstract][Full Text] [Related]
18. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.
Rohleder C; Müller JK; Lange B; Leweke FM
Front Pharmacol; 2016; 7():422. PubMed ID: 27877130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
